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ABSTRACT
Objective: This study was performed to identify risk factors and to determine the attributable mortality and clinical 
outcomes of nosocomial Acinetobacter bacteremia in our intensive care unit. 
Methods: A retrospective case-control (1:1) study was conducted in a tertiary, academic hospital composed of 300 
beds. The control group consisted of 54 consecutive patients with negative blood cultures, matched by sex, age (±10 
years), primary and secondary diagnosis, operative procedures, and date of admission. 
Results: There was a trend for a longer median duration of hospitalization among the patient group compared with the 
control group (25.0 versus 8.0 days; p=0.001). Patients with Acinetobacter bacteremia had significantly more hemody-
namic instability (hypoxia, shock) (p=0.001). We detected that the presence of risk factors such as mechanical ventila-
tion, central venous catheter, anemia, thrombocytopenia, hypoalbuminemia and impairment in creatinine clearance 
was higher in the patient group than in the control group (p<0.004). Thirty-three (61.1%) of the cases died whereas 
14 (25.9%) of the controls died (p=0.001). The attributable mortality was estimated as 35.2%. Of the 54 Acinetobacter 
isolates, 44 (81.5%) were resistant to two or more different antibiotic classes.
Conclusion: In critically ill patients, Acinetobacter bacteremia is associated with a significantly increased mortality rate. 
Central venous catheter insertion, mechanical ventilation, long length of hospital stay and concomitant metabolic dis-
ease were risk factors for the presence of bacteremia. J Microbiol Infect Dis 2013;3(4): 157-162
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Hastane kökenli Acinetobacter bakteriyemisinde risk faktörleri: Yoğun bakım hastalarında 
bir vaka kontrol çalışması
ÖZET
Amaç: Bu çalışma yoğun bakımda gelişen hastane kökenli Acinetobacter bakteriyemilerinde risk faktörlerinin belirlen-
mesi, hastalığın klinik sonuçlarının ve bakteriyemiye atfedilen mortalitenin saptanması için yapıldı.
Yöntemler: Çalışma, 300 yataklı üçüncü basamak bir üniversite hastanesinde retrospektif vaka kontrollü (1:1) olarak ger-
çekleştirildi. Kontrol grubu; kan kültürü negatif, yaş (± 10), cins, birincil ve ikincil tanıları, operasyon öyküleri ve başvuru 
zamanları vaka grubu ile eşleşen 54 ardışık hastadan oluşturuldu.
Bulgular: Hasta grubunda ortalama yatış süresi kontrol grubuna göre uzundu (sırasıyla 25.0 ve 8,0 gün, p=0,001). Aci-
netobacter bakteriyemisi olan hastalarda hemodinamik instabilite (hipoksi, şok) daha sık gözlendi (p=0,001). Mekanik 
ventilasyon, santral venöz kateterizasyon, anemi, trombositopeni, hipoalbüminemi ve kreatinin klirensinde bozulma gibi 
risk faktörleri hasta grubunda kontrol grubuna göre fazlaydı (p<0,004). Kontrol grubunda 14 (% 25,9) hasta kaybedilir-
ken, hasta grubunda bu sayı 33 (% 61,1) olarak bulundu (p=0.001). Atfedilen mortalite % 35,2 olarak hesaplandı. Ellidört 
Acinetobacter izolatının 44’ü (% 81,5) iki ve daha fazla antibiyotik grubuna dirençliydi.
Sonuçlar: Acinetobacter bakteriyemisi özellikle kritik hastalarda mortaliteyi belirgin olarak arttırmaktadır. Santral venöz 
kateter varlığı, mekanik ventilasyon, uzun hastanede yatış süresi, eşlik eden metabolik hastalıklar bakteriyemi için risk 
faktörleridir. 
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INTRODUCTION
Acinetobacter species have emerged as important 
hospital-acquired pathogens causing infectious out-
breaks in critically ill patients.1 These microorgan-
isms are important because, they are nosocomial 
pathogens difficult to control, although they are not 
particularly virulent. The persistence of endemic 
Acinetobacter strains in the intensive care unit (ICU) 
seems to be related to their ability for long-term sur-
vival on inanimate surfaces in the patients’ immedi-
ate environment as well as to their widespread re-
sistance to major antimicrobial agents.1,2 Changes 
in health care policies, infection-control practices, 
antimicrobial use and resistance profile in the past 
20  years  may  have  influenced  the  frequency  of 
these gram-negative organisms among the patho-
gens associated with hospital-acquired infections.3,4 
Members of the genus Acinetobacter, particularly 
Acinetobacter baumanii, are implicated in a wide 
spectrum of infections, especially nosocomial pneu-
monia, and bacteremia. Acinetobacter species have 
recently emerged as the leading cause of nosoco-
mial bloodstream infections in intensive care units. 
Important increases in mortality rates and duration 
of ICU stay attributable to Acinetobacter infections 
have been reported in several case-control studies 
of critically ill patients.5-8 This study was performed 
to identify risk factors and to determine the attribut-
able mortality and outcome of Acinetobacter bacte-
remia in our intensive care unit. 
METHODS
Clinical setting
The study was performed in the Anesthesiology and 
Reanimation Intensive Care Unit of the Celal Bayar 
University Hospital in Manisa, Turkey. This ICU has 
a capacity of 10 patients and serves critically ill pa-
tients from the whole hospital. 
Patients
Fifty-four patients who developed nosocomial Aci-
netobacter bacteremia were matched with 54 con-
trol patients without nosocomial Acinetobacter bac-
teremia from January 2001 to December 2006. This 
period was chosen because Acinetobacter infec-
tions were not epidemic in our hospital yet. Controls 
were defined as the consecutive patients with nega-
tive blood cultures, matched by gender, age (+/- 10 
years), primary and secondary diagnosis, operative 
procedures, and date of admission. 
Definitions
If a patient who presented to the hospital 48 hours 
ago and / or had a history of hospitalization within 
the last two weeks prior to their admission to the 
hospital has Acinetobacter spp growth in at least 
one blood culture result in addition to the signs and 
symptoms consistent with bloodstream infections is 
defined as having nosocomial Acinetobacter bacte-
remia.
If a patient had more than one episode of Aci-
netobacter bacteremia during the study, only the first 
bacteremic episode was included in the analysis.
The physicians to ensure whether it was a 
causative agent for infection or contamination eval-
uated each positive blood culture. This decision was 
based on physical examination findings, body tem-
perature, clinical course and microbiological results. 
Bacteremia was defined according to the criteria es-
tablished by the Centers for Disease Control and 
Prevention.9 The presence of contaminants in the 
blood cultures was defined as a positive culture re-
sult without concurrent evidence of infection. These 
cases were excluded from the analysis.
Bacteremia was considered to be secondary 
if a clinically and microbiologically documented 
source (e.g. pneumonia, wound infection, and/or 
urinary tract infection) of Acinetobacter BSI was 
identified. Primary Acinetobacter BSI was defined 
by the absence of an identifiable source of infec-
tion, whether an intravascular catheter was in place. 
Catheter-related bacteremia was diagnosed when 
the same strain was isolated in blood cultures and 
semiquantitative culture of a catheter segment 
(yielding ≥15 colonies) or if there was a clear clinical 
response after the removal of the catheter. Potential 
cases were excluded if samples for blood culture 
were drawn through an intravascular catheter, if any 
other microorganism was isolated from the same 
set of blood cultures, or if another microorganism 
was isolated from cultures obtained during the 72 
hours before or 72 hours after Acinetobacter BSI 
was firstly isolated.
The Acute Physiology and Chronic Health 
Evaluation (APACHE) II scoring system devised by 
Knaus et al. was used to assess the severity of an 
acute illness.10 We recorded the APACHE II severity 
score when the blood culture specimen was drawn. 
For the control group, these values were calculated 
when they were included in the study.
Clinical characterization
The presence of the following comorbid conditions 
was also documented: neutropenia, immunosup-
pressive disease, corticosteroid usage, receipt of 
immunosuppressive agents within 30 days prior 
to bacteremia, diabetes mellitus, trauma, chronic Tunger O, et al. Risk factors for nosocomial Acinetobacter bacteremia 159
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obstructive pulmonary disease and chronic renal 
failure.  Risk  factors  defined  during  the  ICU  stay 
were as follows: serious surgical operation during 
2 weeks before episode, mechanical ventilation (if 
administered at the time of the blood culture speci-
men was taken) and the presence of central venous 
catheter.
Total leukocyte and neutrophil count, platelet 
count, hemoglobin concentration, erythrocyte sedi-
mentation rate, C-reactive protein, albumin level, 
and creatinine clearance were recorded when the 
blood was drawn for culture.
Clinical events, which developed during ICU 
stay, were cardiopulmonary arrest, respiratory fail-
ure, cardiogenic pulmonary edema, sepsis, severe 
sepsis or septic shock, and multi-organ dysfunction 
syndrome (MODS), as defined elsewhere. When re-
spiratory failure or shock was present at ICU admis-
sion, a 48-h interval during which clinical signs were 
not present was required to define a new onset of 
these events.
Microbiological methods
All blood cultures were processed by microbiology 
laboratory of our hospital using the BACTEC 9120 
blood culture system (Becton Dickinson Diagnostic 
Instrument System, Sparks, MD, USA) with an in-
cubation period of 5 days. All positive cultures were 
Gram-stained and sub-cultured on blood agar plates 
and eosin-methylene blue agar plates for further 
identification.  Confirmation  of  Acinetobacter iden-
tification was performed by using commercial kits 
(BBL Crystal GP; N/F; ID-Becton Dickinson, USA). 
Antibiotic susceptibility testing was performed by 
using the disk diffusion method according to the 
recommendations of the Clinical and Laboratory 
Standards Institute.11 
Statistical analysis
Continuous variables were described as the mean 
value with the standard deviation and the median, 
too. Normality assumption for continuous variables 
was tested using the Kolmogorov Smirnov test. 
Differences in the means of normally distributed 
variables were evaluated by using Student’s t-test 
whereas the Mann–Whitney U-test was used for 
non-Gaussian variables. Categorical variables were 
analyzed using the Chi-square test or Fisher’s exact 
test. 
A multivariate analysis with logistic regression 
was performed to identify risk factors independently 
associated with mortality of the whole group. All p 
values were 2-tailed; p values less than or equal to 
0.05 were considered as statistically significant. All 
statistical analyses were performed by using Statis-
tical Package for Social Sciences (SPSS Windows 
version 16.0).
RESULTS
Patients were included in the analysis and controls 
were selected in the study period. There was a 
trend for a longer median duration of hospitalization 
among cases compared to controls (25.0 versus 8.0 
days; p=0.001). There were no significant differenc-
es between the cases and control patients in terms 
of demographic characteristics and the underlying 
illness. Demographic and clinical characteristics 
of the patients with Acinetobacter bacteremia and 
controls were summarized on Table 1.
The median interval between admission and 
the Acinetobacter bacteremia was 12.8 (3-65) days 
(mean, 14.7 days). The most common source of 
Acinetobacter bacteremia was intravascular cath-
eters (17 cases, 31.5%) followed by the respiratory 
tract (8 cases, 14.8%). Only a minority of the pa-
tients had other sources, including the urinary tract 
(7.4%) and surgical wounds (3.7%). There were 23 
bacteremic episodes (42.6%) in which the source of 
bacteremia could not be identified.
Fever was the most common sign of Acineto-
bacter bacteremia (48 cases - [88.8%]), followed by 
hemodynamic instability (31 cases - 57.4%). The 
patients with Acinetobacter bacteremia had sig-
nificantly more hemodynamic instability (APACHE 
II score of ≥16, hypoxia, shock) than did controls. 
Septic shock was seen in 31 patients in the case 
group. The subjects in the case group underwent 
mechanical ventilation and invasive procedure 
more, suffered anemia, trombocytopenia, hypoal-
buminemia more and had lower creatinine clear-
ance levels than did the subjects in control group 
(p< 0.05).
Of the 54 Acinetobacter isolates, 41 were re-
sistant to amikacin, 20 to ampicillin-sulbactam, 49 
to piperacillin-tazobactam, and 38 (70.4%) to imipe-
nem. Forty-four (81.5%) isolates were resistant to 2 
or more different antibiotic classes. Initial empirical 
antibiotic therapy was instituted for all the case pa-
tients, but appropriate antibiotic therapy was con-
sidered for only 9 of them (16.7%). After the results 
of susceptibility tests were received, treatment was 
changed appropriately for all the case patients.
Mortality was evaluated during 30 days after the 
blood culture was performed. Thirty-three (61.1%) 
of the case patients died during hospitalization, 
compared with 14 (25.9%) of the control patients Tunger O, et al. Risk factors for nosocomial Acinetobacter bacteremia 160
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(p=0.001). Attributable mortality is determined by 
subtracting the crude mortality rate of the controls 
from the crude mortality rate of the cases. Attribut-
able mortality was 35.2%.
Variables
Case patients
(n=54)
Control patients
(n=54) p value
Age, mean ±SD 53.05±22.30 47.90±20.58 0,008
Male sex 39 (72.2) 32 (59,3) NS
Hospitalization duration, median (25th-75th) 25.0 (12,75-40.0) 8.0 (5.75- 12.0) 0.001
APACHE II score
 ≤15 46 (85.2) 53 (98.1) 0.031
 ≥16  8 (14.8) 1 (1.9)
Immunosuppressive disease  31 (57,4) 22 (40.7) NS
Trauma 13 (24.1) 12 (22.2) NS
Chronic obstructive pulmonary disease 9 (16.7) 5 (9,3) NS
Chronic renal failure 3 (5.6) 0 (0.0) NS
Diabetes mellitus 8 (14.8) 6 (11.1) NS
Steroid usage 17 (31.5) 10 (18.5) NS
Serious surgical operation 7 (13.0) 3 (5.6) NS
Central venous catheter 32 (59.3) 54 (100.0) 0.001
Mechanical ventilation 48 (88.9) 39 (72.2) 0.029
Anemia  42 (77.8) 15 (27.8) 0.001
Trombocytopenia 31 (57.4) 16 (29.6) 0.004
Hypoalbuminemia 38 (70.4) 25 (46.3) 0.011
Decreased creatinine clearance 17 (31.5) 7 (12.9) 0.021
Hypoxia 29 (53.7) 10 (18.5) 0.001
Shock 31 (57.4) 12 (22.2) 0.001
Mortality 33 (61.1) 14 (25.9) 0.001
NS=Not significant (p>0.05), SD=Standard deviation
Table  1. Demographic 
and clinical characteris-
tics of patients with Aci-
netobacter bacteremia 
and control patients
Multivariate analysis using a logistic regression 
model including the variables associated with mor-
tality by univariate analysis (p<0.05) showed that 
the significant independent risk factors for mortality 
were older age, receipt of mechanical ventilation, 
and Acinetobacter bacteremia (Table 2).
Table 2. The risk factors for mortality by multivariate anal-
ysis
Parameters OR 95%CI p value
Acinetobacter bacteremia 2.63 1.02-6.82 0.045
Older age 4.74 1.31-17.15 0.018
Mechanical ventilation 3.12 0.98-9.89 0.05
OR= Odds ratio, CI= Confidence interval
DISCUSSION
Nosocomial Acinetobacter bacteremia is an impor-
tant health-care problems leading to increased mor-
bidity and mortality in intensive care units (ICU).3,12 
Acinetobacter infections and colonization cause se-
rious consequences in our hospital too. The aim of 
this matched case-control study was to determine 
the risk factors affecting the development of Aci-
netobacter bacteremia in our Anesthesia and Re-
animation ICU. 
The risk factors playing a role in endemic colo-
nization of Acinetobacter spp and epidemic infec-
tions might vary depending on the disease and hos-
pital flora. Main risk factors determined in the previ-
ous studies are: bacterial colonization in the patient, 
the history of broad-spectrum antibiotic usage, prior 
infection, hyperalimentation, burns involving more Tunger O, et al. Risk factors for nosocomial Acinetobacter bacteremia 161
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than 50% of the total body surface area and the 
presence of invasive procedures (arterial catheter, 
abdominal drainages, central venous catheter, me-
chanical ventilation, nasogastric tube, peripheral 
vein catheter, pulmonary artery catheter, thoracic 
drainage, and urinary catheter).7,13-15 In our study, 
we detected that the presence of risk factors such 
as mechanical ventilation, central venous catheter, 
anemia, thrombocytopenia, hypoalbuminemia and 
impairment in creatinine clearance was higher in 
the patient group than in the control group. Prolon-
gation of hospitalization period also plays a pivotal 
role in the development of Acinetobacter bactere-
mia since it leads to an increased colonization of 
these bacteria in the patient.8,16 In the present study, 
the hospitalization period in the patient group was 
three times longer than that of in the control group. 
The difference between two groups was found to be 
statistically significant.
There are a great number of factors affecting 
the severity and the prognosis of Acinetobacter bac-
teremia. In order to evaluate the extent of the dis-
ease severity in an intensive care unit, the APACHE 
II scoring system was used. It was detected that the 
APACHE II score was significantly higher in the pa-
tient group compared with the control group. The 
same condition is valid for shock and hypoxia vari-
ables indicating hemodynamic instability. In multi-
variate analysis conducted to identify independent 
risk factors for mortality, the presence of Acineto-
bacter bacteremia was detected to be the sole inde-
pendent risk factor. In addition, mechanic ventilation 
and age were detected to be the independent risk 
factors for mortality. However, APACHE II score, hy-
poxia and shock did not constitute independent risk 
factors.
Resistant bacterial infection is another impor-
tant challenge in places such as intensive care units 
where increasing amount of antibiotics are used. 
Multiple drug resistance is considerably high par-
ticularly in Acinetobacter spp.4,17-19 The concept of 
multiple drug resistance represents being resistant 
to at least two of the following: antipseudomonal 
cephalosporins/penicilins, antipseudomonal beta-
lactam/beta lactamase inhibitors, carbapanems, 
fluoroquinolones and aminoglycosides. In our study, 
we detected that 81.5% of the species were mul-
tiple drug resistant (MDR) and 70.4% of the species 
were resistant to carbapenems. Therefore, initial 
empirical antibiotic therapy was appropriate for only 
nine patients (16.7%). Tigen et al. reported signifi-
cant results about antibiotherapy for Acinetobacter 
infections. In this study; age, age greater than 65 
years, APACHE II score more than 20 at baseline 
as well as delayed appropriate administration were 
found to be associated with mortality.20 However, 
due to the small number of the patients, we could 
not perform a comparison between the appropriate 
and inappropriate therapy group. 
In clinical studies so far, crude rates of mortal-
ity due to Acinetobacter bacteremia have been pre-
sented within a wide range (6-57%).21,22 Since true 
bacteremia cases were enrolled and polymicrobial 
growths were excluded, we found that crude mortal-
ity rate due to Acinetobacter was significantly higher 
in our matched case-control study than in the con-
trol group. Not only the infection but also other risk 
factors have an effect in on crude mortality rates. 
It is important to calculate attributable mortality in 
an attempt to point out the contribution of only Aci-
netobacter bacteremia to total mortality rate. Stud-
ies on attributable mortality in of Acinetobacter 
bacteremia in intensive care patients reported that 
the rates ranged from 19% to 35%.6,23 The overall 
mortality of Acinetobacter infections was 52.5% 
and 72% during 30 days according to the results 
of studies from Turkey.19,24 In our study, the rate of 
attributable mortality due to Acinetobacter bactere-
mia was found to be high (35.2%). The reason why 
crude and attributable mortality rates in our study 
was higher than in other studies might be that the 
multiple drug resistance was high in species and 
infection control precautions were not applied ap-
propriately. Besides, such factors as the differences 
in the studied patient population and the severity of 
the matched underlying diseases might have had a 
role in the increased rates. In our study, we aimed to 
make a one-to-one comparison between the patient 
group and the control group in terms of age, gender, 
underlying diseases, and hospitalization time in ICU 
in order to minimize the effects of interfering factors. 
Acinetobacter infections showed an endemic 
pattern during the study period. Epidemic Acineto-
bacter  outbreaks  with  an  exact  identified  source 
have not been reported yet. Unfortunately, despite 
all the precautions taken, the development of en-
demic infections has not been completely prevent-
ed. This point should be kept in mind while the find-
ings are interpreted and thus the results should not 
be generalized.
There are several limitations of this study in-
cluding its retrospective design, a single center ex-
perience, a small number of patients, and non-ho-
mogeneous therapy. Our retrospective study design 
is subject to management decisions for patients 
were uncontrolled.
Each unit or hospital should attempt to identify 
the responsible risk factors while performing sur-Tunger O, et al. Risk factors for nosocomial Acinetobacter bacteremia 162
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veillance for the problematic microorganisms and 
consider these results in defining hospital infection 
control policies. In conclusion, strict control precau-
tions, appropriate antibiotic use and appropriate 
use of invasive procedures are important control 
methods to prevent the development of Acineto-
bacter infection. 
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